Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Stock Has Consensus Target Price of $16.00 According to Brokerages

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $16.00.

NTHI has been the topic of several analyst reports. Wall Street Zen lowered shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings downgraded shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Roth Capital started coverage on shares of Neonc Technologies in a research note on Thursday, September 24th. They set a “buy” rating on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $15.00 target price on shares of Neonc Technologies in a report on Tuesday, September 8th.

Insider Buying and Selling

In other Neonc Technologies news, CEO Thomas C. Chen purchased 12,757 shares of the stock in a transaction on Tuesday, August 18th. The shares were purchased at an average price of $5.49 per share, with a total value of $70,035.93. Following the completion of the transaction, the chief executive officer directly owned 13,705 shares in the company, valued at $75,240.45. This represents a 1,345.68% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Amir F. Heshmatpour purchased 37,000 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average price of $3.67 per share, for a total transaction of $135,790.00. Following the purchase, the chief executive officer owned 3,133,000 shares in the company, valued at $11,498,110. This trade represents a 1.20% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 134,812 shares of company stock worth $530,149.

Institutional Investors Weigh In On Neonc Technologies

Hedge funds and other institutional investors have recently modified their holdings of the company. Global Retirement Partners LLC acquired a new stake in Neonc Technologies in the 2nd quarter worth about $126,000. BlackRock Inc. acquired a new position in shares of Neonc Technologies during the 2nd quarter worth approximately $815,000. Westmount Partners LLC increased its holdings in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares during the period. Finally, Bank of America Corp DE bought a new position in shares of Neonc Technologies during the second quarter worth approximately $1,017,000.

Neonc Technologies Stock Up 2.4%

NASDAQ:NTHI opened at $2.99 on Friday. The stock’s 50-day simple moving average is $3.88 and its 200 day simple moving average is $4.63. Neonc Technologies has a 52-week low of $2.88 and a 52-week high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.